RecruitingNot ApplicableNCT06221787

Stem Cell Derived Exosomes in the Treatment of Melasma and Its Percutaneous Penetration

Sponsor

Fujian Medical University Union Hospital

Enrollment

80 participants

Start Date

Apr 1, 2022

Study Type

INTERVENTIONAL

Conditions

Melasma

Summary

Melasma is a refractory skin disease due to its complex pathogenesis and difficult treatment. Studies have found that human umbilical cord mesenchymal stem cell-derived exosomes (hUCMSC-Exos) could serve as a novel cell-free therapeutic strategy in regenerative and aesthetic medicine. It could potentially treat melasma, but the skin barrier is a challenge. This study aims to explore the safety and efficacy of hUCMSC-Exos in the treatment of melasma and means to promote its percutaneous penetration.

Eligibility

Min Age: 18 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a procedure called 1565 nm non-ablative fractional laser combined with hUCMSC-Exos, a procedure called 1565 nm non-ablative fractional laser combined with normal saline, and others for people with melasma. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 60 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURE1565 nm non-ablative fractional laser combined with normal saline

After 1565 nm non-ablative fractional laser treatment, patients with melasma were smeared with normal saline and to compared with those smeared with exosomes after laser treatment.

PROCEDUREmicroneedles combined with hUCMSC-Exos

the hUCMSC-Exos were applied while rolling a microneedle roller and to compared with those used 1565 nm non-ablative fractional laser or PBASM combined with hUCMSC-Exos.

PROCEDURE1565 nm non-ablative fractional laser combined with hUCMSC-Exos

After 1565 nm non-ablative fractional laser treatment, patients with melasma were smeared with hUCMSC-Exos and to compared with those smeared with normal saline after laser treatment.What's more,compared with those used microneedles or PBASM combined with hUCMSC-Exos.

PROCEDUREPBASM combined with hUCMSC-Exos

a plasma named Peninsula Blue Aurora Shumin Master (PBASM) rolling each area for 8-10 min before applying the hUCMSC-Exos in the entire face. And to compared with those used 1565 nm non-ablative fractional laser or microneedles combined with hUCMSC-Exos.